SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Inclusion Criteria:

• Confirmed relapsed/ refractory multiple myeloma

• Measurable disease including at least one of the following criteria:

• Serum M-protein ≥ 0.5 g/dL

• Urine M-protein ≥ 200 mg/24h

• Serum free light chain assay: involved free light chain (FLC) level greater orequal to 100 mg/L provided serum free light chain ratio is abnormal

• Bone marrow plasma cells ≥ 10% total bone marrow cells

• ≥ 1 prior line of therapy

• Planned treatment with a carfilzomib/daratumumab/dexamethasone regimen

• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

• Absolute neutrophil count: ≥ 3 x 10^9/L

• Platelets: ≥ 75 x 10^9/L

• Hemoglobin: ≥ 7 g/dL

• Total bilirubin: ≤ 1.5 x upper limit of normal (ULN): ≤ 3.0 x ULN for Gilbert'ssyndrome

• Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT]) /alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]): ≤ 3 xULN

• Renal Function: Estimated creatinine clearance ≥ 45 mL/min (Cockroft-Gault)

• Left ventricular ejection fraction of at least 50%

• Participants of child-bearing potential must agree to use adequate contraceptivemethods (e.g., hormonal or barrier method of birth control; abstinence) prior tostudy entry and for 6 months following the last dose of the investigational drug.Should a woman become pregnant or suspect she is pregnant while she or her partneris participating in this study, she should inform her treating physician immediately

• Participant must understand the investigational nature of this study and sign anIndependent ethics committee/institutional review board approved written informedconsent form prior to receiving any study related procedure

Exclusion Criteria:

• Patients with non-secretory myeloma, systemic light chain amyloidosis or,plasmacytoma

• Intolerance to SX-682 or any other of the treatment components

• Refractory to prior carfilzomib (i.e. relapse or progression on or within 60 daysafter completion of treatment)

• Refractory to prior daratumumab (i.e. relapse or progression on or within 60 daysafter completion of treatment)

• Concomitant medication(s) known to be (a) a strong inhibitor or inducer of CYP3A4,or (b) QT prolonging as defined in the drug's approved label, with the exception ofdrugs that are considered absolutely essential for the care of the subject or if theinvestigator believes that beginning therapy with such medication is vital to anindividual subject's care while on study, and in either case, there is noalternative medication

• Electrocardiogram (ECG) demonstrating a corrected QT (QTc) interval > 470 msec orpatients with congenital long QT syndrome

• Coronary artery bypass, angioplasty, vascular stent, myocardial infarction, anginaor congestive heart failure in the last 6 months

• Uncontrolled intercurrent illness including, but not limited to, ongoing or activeinfection, symptomatic congestive heart failure, unstable angina pectoris, cardiacarrhythmia, class III or IV heart failure (New York Heart Association functionalclassification system) or psychiatric illness/social situations that would limitcompliance with study requirements

• History of hepatitis B, C or HIV

• Known active bacillus tuberculosis infection

• Pregnant or nursing female participants

• Unwilling or unable to follow protocol requirements

• Any condition which in the investigator's opinion deems the participant anunsuitable candidate to receive study drug